Regulation of tumor growth by IFN-γ in cancer immunotherapy

Bach EA, Aguet M, Schreiber RD: The IFN-γ receptor: A paradigm for cytokine receptor signaling. Annu Rev Immunol 1997; 15:563. Dighe AS, Farrar MA, Schreiber RD: Inhibition of cellular responsiveness to interferon-γ (IFNγ) induced by overexpression of inactive forms of the IFNγ receptor. J Biol Chem 1993;268:10,645. Kaplan DH, Shankaran V, Dighe AS, et al.: Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998;95:7556. Taniguchi T: Transcription factors IRF-1 and IRF-2: Linking the immune responses and tumor suppression. J Cell Physiol 1997; 173:128. Nozawa H, Oda E, Ueda S, et al.: Functionally inactivating point mutation in the tumor-suppressor IRF-1 gene identified in human gastric cancer. Int J Cancer 1998; 77:522. Nastala CL, Edington HD, McKinney TG, et al.: Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol 1994;153:1697. Ogawa M, Yu WG, Umehara K, et al.: Multiple roles of interferon-γ in the mediation of interleukin 12-induced tumor regression. Cancer Res 1998;58:2426. Weiskirch LM, Pan Z-K, Paterson Y: The tumor recall response of antitumor immunity primed by a live, recombinant Listeria monocytogenes vaccine is comprised of multiple effector mechanisms. Clin Immunol 2001; (In press). Dighe AS, Richards E, Old LJ, Schreiber RD: Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFNγ receptors. Immunity 1994;1:447. Seliger B, Hohne A, Knuth A, et al.: Analysis of the major histocompatibility complex class 1 antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. Cancer Res 1996;56: 1756. Seliger B, Hammers S, Hohme A, et al.: IFN-gamma-media ledcoor-dinated transcriptional regulation of the human TAP-1 and LMP-2 genes in human renal cell carcinoma. Clin Cancer Res 1997; 3:573. Webber JS, Rosenberg SA: Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro. Cancer Res 1998;48:5818. Ritter M, Huber C, Aubock J, et al.: Lytic susceptibility of target cells to cytotoxic T cells is determined by their constitutive major histocompatibility complex class I atigen expression and cytokine-induced activation status. Immunology 1994;81:569. Boraschi D, Censini S, Tagliablue A: Interferon-gamma reduces macrophage-suppressive activity by inhibiting prostaglandin E2 release and inducing interleukin 1 production. J Immunol 1984; 133:764. Naganuma H, Sasaki A, Satoh E, et al.: Down-regulation of transforming growth factor-beta and interleukin-10 secretion from malignant glioma cells by cytokines and anticancer drugs. J Neurooncol 1998;39:227. Torre-Amione G, Beauchamp RD, Koeppen H, et al.: A highly immunogenic tumor transfected with a murine transforming growth factor type β1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 1990;87:1486. Tamenbaum CS, Tubbs R, Armstrong D, Finke JH, Bukowski RM, Hamilton TA: The CXC chemokines 1P-10 and Migrane necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol 1998;161:927. Bukowski RM, Rayman P, Molto L, et al.: Interferon-gamma and CXC chemokine induction by interleukin 12 in renal cell carcinoma. Clin Cancer Res 1999; 5:2780. Mukai S, Kjaergaard J, Shu S, Plautz GE: Infiltration of tumors by systemically tranferred tumor-reactive T lymphocytes is required forantitumor efficacy. Cancer Res. 1999;59:5245. Springer TA Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994;76:301. Butcher EC, Picker LJ: Lymphocyte homing and homeostasis. Science. 1996;272:60. Kunz M, Toksoy A, Goebeler M, Engelhardt E, Brocker E.-B.. Gillitzer R: Strong expression of the lymphoattractant C-X-C chemokine Mig is associated with heavy infiltration of T cells in human malignant melanoma. J Pathol. 1999;189:552. Sgadari C, Angiolillo AL, Tosato G: Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein-10. Blood. 1996;87:3877. Coughlin CM, Salhany KE, Gee MS, et al.: Tumor cell responses to IFN-γ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 1998;9:25. Majewski S, Marczak M, Szmurlo A, Jablonska S, Bollag W: Interleukin-12 inhibits angiogenesis induced by human tumor cell lines in vivo. J Invest Dermatol 1996; 106:1114. Dias S, Boyd R, Balkwill F: IL-12 regulates VEGF and MMPs in a murine breast cancer model. Int J Cancer 1998;78:361. Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ: Evidence for the involvement of endothelial cell integrin αvβ3 in the disruption of the tumor vasculature induced by TNF and IFN-γ. Nat Med 1998;4:408. Beatty GL, Paterson Y: CD4+ T cells control early tumor development of a class 11 negative tumor through IFN-γ dependent inhibition of angiogenesis. J Immunol 2001; (in press). Qin Z, Blankenstein T: CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFNγ receptor expression by nonhematopoietic cells. Immunity 2000;12:677. Beatty GL, Paterson Y: IFN-γ can promote tumor evasion of the immune system in vivo by down-regulating cellular levels of an endogenous tumor antigen. J Immunol 2000;165:5502. Morel S, Levy F, Burelet-Schlitz O, et al.: Processing of some antigens by the standard but not by the immun proteasome results in poor presentation by dendritic cells. Immunity 2000;12:107. Maeurer MJ, Gollin SM, Martin D, et al.: Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with down regulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest 1996;98:1633. Lee KH, Panelli MC, Kim CJ, et al.: Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination. J Immunol 1998;161:4183. Virelizier JL, Arenzana-Seisdedos F: Immunological functions of macrophages and their regulation by interferons. Med Biol 1985; 63:149. Germain RN, Margulies DH: The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol 1993;11:403. Kantor J, Tran R, Greiner J, et al.: Modulation of carcinoembryonic antigen messenger RNA levels in human colon carcinoma cells by recombinant human gamma-interferon. Cancer Res 1989;49: 2651. Greiner JW, Guadagni F, Goldstein D, et al.: Evidence for the elevation of serum carcinoembryonic antigen and tumor-associated glycoprotein-72 levels in patients administered interferons. Cancer Res 1991;51:4155. Mortarini R, Belli F, Parmiani G, Anichini, A: Cytokine-mediated modulation of HLA-class 11, ICAM-1, LFA-3 and tumor-associated antigen profile of melanoma cells. Comparison with anti-proliferative activity by rIL1-beta, rTNF-alpha, rIFN-gamma rIL4 and their contribution. Int J Cancer 1990;45:334. Meyskens FL, Kopecky K, Samson M, et al.: Recombinant human interferon γ:adverse effects in high-risk stage I and II cutaneous malignant melanoma. J Natl Cancer Inst 1990;82:1071. Kowalzick L, Weyer U, Lange P, Breitbart EW: Systemic therapy of advanced metastatic malignant melanoma with a combination of fibroblast interferon-beta and recombinant interferon-gamma. Dematologica 1990;181:298. Boehm U, Klamp T, Groot M, Howard JC: Cellular responses to interferon-γ. Annu Rev Immunol 1997;15:749. Fransen L, Van Der Heyden J Ruysschaert R, Fiers W: Recombinant tumor necrosis factor: its effect and its synergism with interferon-gamma on a variety of normal and transformed human cell lines. Eur J Cancer Clin Oncol 1986;22:419. Tsujimoto M, Yip YK, Vilcek J: Interferon-gamma enhances expression of cellular receptor for tumor necrosis factor. J Immunol 1986;136:2441. Yonehara S, Ishii A Yonehara M: A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigenco-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989;169:1747. Ossina NK, Cannas A, Powers VC, et al.: Interferon-γ modulates a p53-independent apoptotic pathway and apoptosis-related gene expression. J Biol Chem 1997; 272:16351. Croft M, Carter LL, Swain SL, Dutton RW: Generation of polarized antigen specific CD8 effector populations: reciprocal actions of IL-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med 1994;180:1715. Sad S, Marcotte R, Mossmann TR: Cytokine induced differentiation of precursor mouse CD8 T cells into cytotoxic CD8 T cells secreting Th1 or Th2 cytokines. Immunity 1995;2:271. Cerwenka A, Carter LL, Reome JB, Swain SL, Dutton RW: In vivo persistence of CD8 polarized T cell subsets producing type 1 or type 2 cytolines. J Immunol 1998;161: 97. Dobrzanski MJ, Reome JB, Dutton RW: Type 1 and type 2 CD8+ effector T cell subpopulation promote long-term tumor immunity and protection to progressively growing tumor. J Immunol 2000;164:916. Yao L, Sgadari C, Furuke K, Bloom ET, Teruya-Feldstein J, Tosato G: Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood 1999;93: 1612. Storkus WJ, Howell DN, Salter RD, Dawson JR, Cresswell P: NK susceptibility varies inversely with target cell class I HLA antigen expression. J Immunol 1987;138: 1657. Ljunggren HG, Sturmhofel K, Wolpert E, Hammerling GJ, Karre K: Transfection of beta 2-microglobulin restores IFN-mediated protection from natural killer cell lysis in YAC-I lymphoma variants. J Immunol 1990;145:380. Moretta A, Biassoni R, Bottino C, Moretta L: Surface receptors delivering opposite signals regulate the function of human NK cells. Semin Immunol 2000;12:129. Mosmann TR, Cherwinski HM, Bond MW, Giedlin MA, Coffman RL: Two types of murine helper T cell clone. I. Definition accord-ing to profiles of lymphokineactivities and secreted proteins. J Immunol 1986;136:2348. Cherwinski HM, Schumacher JH, Brown KD, Mosmann TR: Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific specific bioassays and monoclonal antibodies. J Exp Med 1987; 166:1229. Nishimura T, Iwakabe K, Sekimoto M, et al.: Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 1999;190:617. Tite J, Janeway Jr CA: Cloned helper T cell can kill B lymphoma cells in the presence of specific antigen. 1a restriction and cograte vs. noncognate interactions in cytolysis. Eur J Immunol 1984; 14:878. Ozaki S, York-Jolley J, Kawamura H, Berzofksy JA: Cloned protein antigen-specific, la-restricted T cells with both helper and cytolytic activities: Mechanisms of activation and killing. Cell Immunol 1987;105:301. Yoshimura A, Shiku H, Nakayama E: Rejection of an IA+ variant line of FBL-3 leukemia by cytotoxic T lymphocytes with CD4+ and CD4−CD8− T cell receptor-alpha beta phenotypes generated in CD8-depleted C57BL/6 mice. J Immunol 1993;150:4900. Echchakir H, Bagot M, Dorothese G, et al.: Cutaneous T cell Lymphoma Reactive CD4+ Cytotoxic T Lymphocyte Clones Display a Th1 Cytokine Profile and Use of Fas-Independent Pathway for Specific Tumor Cell Lysis. J Invest Dermatol 2000;115:74. Greenberg PD: Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 1991;49:281. Pandoll DM, Topalian SL: The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 1998;10:588. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H: Role of bone marrow-derived cells in presenting MHC class 1-restricted tumor antigens. Science 1994;264:961. Mumberg D, Monach PA, Wanderling S, et al.: CD4+ T cells eliminate MHC class 11-negative cancer cells in vivo by indirect effects of IFN-γ. Proc Natl Acad Sci USA 1999;96:8633. Bennett SR, Carbone FR, Karamalis F, Miller JF, Heath WR: Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J Exp Med 1997; 186:65. Greenberg PD, Kern DE, Cheever MA: Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2− T cells. Tumor eradication does not require participation of cytotoxic T cells. J. Exp. Med. 1985;161: 1122. Xie K, Huang S, Dong Z, et al.: Transfection with inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J Exp Med 1995; 181:1333. Folkman J: Antiangiogenic gene therapy. Proc Natl Acad Sci USA 1998;95:9064. Streiter RM, Polverini PJ, Arenberg DA, Kunkel SK: The role of CXC chemokines as regulators of angiogenesis. Shock 1995;4:155. Arenberg DA, Kunkel SL, Polverini PJ, et al.: Interferon-α inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 1996;184:981. Sgadari C, Farber JM, Angiolillo AL, et al.: Mig, the monokine induced by interferon-γ, promotes tumor necrosis in vivo. Blood 1997; 89:2635.